New drug cocktail aims to stop deadly transplant complication
NCT ID NCT06315309
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This phase 2 trial tests whether a new dosing schedule of anti-thymocyte globulin (ATG), combined with tacrolimus and low-dose methotrexate, can prevent acute graft-versus-host disease (GVHD) in adults aged 18-60 receiving a stem cell transplant for blood cancers like leukemia. The study enrolls 29 participants and measures success as being alive and free of severe GVHD or cancer relapse one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-thymocyte globulin (ATG), tacrolimus, and methotrexate
What this could lead to
If successful, this approach could reduce the risk of severe graft-versus-host disease (GVHD) after stem cell transplant, improving survival and quality of life for blood cancer patients.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The drug combination also carries risks like infection and organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.